Published in Genomics and Genetics Weekly, February 25th, 2005
Similar to the previously announced clinical trial in type I diabetes, this type 2 diabetes clinical trial will be conducted in the United States and will evaluate the efficacy, safety, and tolerability of a 28-day course of daily E1-I.N.T. treatments with a 6-month follow-up.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.